EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Lipoxin A4 (LXA4) versus Nanolipoxin A4 (Nano-LXA4) for osteosarcoma

Natália Cristina Gomes-da-Silva, Amanda Cavalcanti, Gabriela Alves, Walter Meohas, Bruna Facchetti, Jamila Alessandra Perini, Luciana Magalhães Rebelo Alencar, Eduardo Ricci-Junior, Pierre B A Fechine, Thereza Christina Barja-Fidalgo, Elaine Cruz Rosas, Ralph Santos-Oliveira

European Journal of Pharmaceutics and Biopharmaceutics · 2026

DOI: 10.1016/j.ejpb.2026.115132 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026. Verfasst von Natália Cristina Gomes-da-Silva und 11 weiteren Autor:innen. Beteiligte Einrichtung: Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de…. Hauptthemen laut MEDLINE: Osteosarcoma, Lipoxins, Nanoparticles, Bone Neoplasms. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipoxin A4 (LXA4) is a specialized pro-resolving lipid mediator with reported antitumor and immunomodulatory activity, but its translation is limited by chemical lability and formulation constraints. Here, we evaluated free LXA4 ("Lipoxin") versus a Pluronic F-127 micellar nanoformulation ("Nanolipoxin") in a human osteosarcoma patient-derived xenograft (PDX) model and assessed In vivo biodistribution using 99mTc labeling. Nanolipoxin exhibited nanostructures with heterogeneous dimensions by SEM (mean length 65 nm; mean diameter 41 nm) and was stored at 2-8 °C to preserve stability. PDX-bearing NSG mice received intraperitoneal treatment (1 µg; n = 3/group) and were monitored for 15 days. Both Lipoxin and Nanolipoxin produced a modest inhibition of tumor growth versus saline, reaching statistical significance on day 9 (*P = 0.0319) and day 15 (**P = 0.0076), while no significant differences were detected between the two active treatments. No clinical toxicity was observed (clinical score 0; stable body weight). Serum biochemistry showed no ALT differences versus control and an AST decrease for both treatments; Nanolipoxin increased lipase relative to control (*P = 0.0334). Dynamic planar scintigraphy demonstrated preferential tumor retention of 99mTc-Nanolipoxin at 60 min (lesion 350.47 kBq), with moderate renal/hepatic uptake and low bladder signal. Collectively, these data support LXA4-based strategies in osteosarcoma and demonstrate that nanoformulation provides tumor-localizing behavior while maintaining an acceptable short-term tolerability profile in this PDX setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaLipoxinsNanoparticlesBone NeoplasmsAntineoplastic AgentsAnimalsHumansMiceTissue DistributionXenograft Model Antitumor AssaysFemaleMice, SCIDCell Line, TumorMicellesPoloxamerSpecialized Pro-Resolving Mediators

Stichwörter der Autor:innen

Cancer progressionDrugsNanotechnologyTherapy

Substanzen

Lipoxinslipoxin A4Antineoplastic AgentsMicellesPoloxamer

Autor:innen und Institutionen

  • Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro, RJ 21941906, Brazil.
  • Unidade de Pesquisa Experimental em Ortopedia, Instituto Nacional de Traumatologia e Ortopedia (INTO), Rio de Janeiro 20940070, Brazil.
  • Centro de Atenção Especializada em Oncologia Ortopédica Instituto Nacional de Traumatologia e Ortopedia (INTO), Rio de Janeiro 20940070, Brazil.
  • Research Laboratory of Pharmaceutical Sciences (LAPESF), Pharmacy Department (DepFarm), Rio de Janeiro State University (UERJ), Rio de Janeiro 23070-200, Brazil.
  • Federal University of Maranhão, Department of Physics, Biophysics Laboratory, Campus Bacanga, São Luís, MA 65080-805, Brazil.
  • LADEG, Laboratory of Pharmaceutical Nanotechnology, Faculty of Pharmacy, DEFARMED, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

Förderung

  • Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

Gomes-da-Silva, N. C., Cavalcanti, A., Alves, G., Meohas, W., Facchetti, B., Perini, J. A., Rebelo Alencar, L. M., Ricci-Junior, E., Fechine, P. B. A., Barja-Fidalgo, T. C., Rosas, E. C., & Santos-Oliveira, R. (2026). Lipoxin A4 (LXA4) versus Nanolipoxin A4 (Nano-LXA4) for osteosarcoma. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2026.115132

Vancouver

Gomes-da-Silva NC, Cavalcanti A, Alves G, Meohas W, Facchetti B, Perini JA, et al. Lipoxin A4 (LXA4) versus Nanolipoxin A4 (Nano-LXA4) for osteosarcoma. European Journal of Pharmaceutics and Biopharmaceutics. 2026. doi:10.1016/j.ejpb.2026.115132

BibTeX
@article{GomesdaSilva2026,
  author = {Gomes-da-Silva, Natália Cristina and Cavalcanti, Amanda and Alves, Gabriela and Meohas, Walter and Facchetti, Bruna and Perini, Jamila Alessandra and Rebelo Alencar, Luciana Magalhães and Ricci-Junior, Eduardo and Fechine, Pierre B A and Barja-Fidalgo, Thereza Christina and Rosas, Elaine Cruz and Santos-Oliveira, Ralph},
  title = {Lipoxin A4 (LXA4) versus Nanolipoxin A4 (Nano-LXA4) for osteosarcoma},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  doi = {10.1016/j.ejpb.2026.115132}
}
Kostenlos starten →